Trials / Withdrawn
WithdrawnNCT03637387
802NP302 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia
A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy of BIIB074 in treating pain experienced by participants with trigeminal neuralgia (TN). The secondary objectives are to investigate the safety and tolerability of BIIB074 in participants with TN and to evaluate the population pharmacokinetic(s) (PK) of BIIB074.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB074 | Administered as specified in the treatment arm |
| DRUG | Placebo | Administered as specified in the treatment arm. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-08-18
- Completion
- 2026-09-29
- First posted
- 2018-08-20
- Last updated
- 2023-05-06
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03637387. Inclusion in this directory is not an endorsement.